Literature DB >> 11854184

Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Francis Gigliotti1, Constantine G Haidaris, Terry W Wright, Allen G Harmsen.   

Abstract

Passive antibody immunoprophylaxis is one method used to protect patients against infection if they are unable to mount an adequate active immune response. Topical application of antibody may be effective against infections at mucosal sites. Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protection against an airborne challenge with P. carinii by intranasal administration of antibody. Immunoglobulin M (IgM) monoclonal antibodies to an epitope shared by mouse and human P. carinii organisms reduced organism numbers by more than 99% under the conditions described. An IgG1 switch variant of one of the IgM monoclonal antibodies was also protective. These experiments provide a model for exploring the utility of this approach in protecting at-risk patients from infection with P. carinii.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854184      PMCID: PMC127758          DOI: 10.1128/IAI.70.3.1069-1074.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

2.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

3.  Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia.

Authors:  F Gigliotti; B A Garvy; A G Harmsen
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors: 
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

5.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis.

Authors:  G Spira; M Paizi; S Mazar; G Nussbaum; S Mukherjee; A Casadevall
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

Review 7.  Antigenic characterization of Pneumocystis carinii.

Authors:  F Gigliotti; C G Haidaris
Journal:  Semin Respir Infect       Date:  1998-12

8.  Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.

Authors:  J B Roths; C L Sidman
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection.

Authors:  A Cassone; M Boccanera; D Adriani; G Santoni; F De Bernardis
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

Review 10.  Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Authors:  L Zeitlin; R A Cone; K J Whaley
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

View more
  42 in total

1.  Novel pneumocystis antigen discovery using fungal surface proteomics.

Authors:  Mingquan Zheng; Yang Cai; Taylor Eddens; David M Ricks; Jay K Kolls
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 2.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 3.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

4.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

6.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 7.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

8.  An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia.

Authors:  Jay K Kolls
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

9.  Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.

Authors:  Jesse Wells; Francis Gigliotti; Patricia J Simpson-Haidaris; Constantine G Haidaris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  MyD88 signaling regulates both host defense and immunopathogenesis during pneumocystis infection.

Authors:  Sheila N Bello-Irizarry; Jing Wang; Carl J Johnston; Francis Gigliotti; Terry W Wright
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.